Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Radiology
|
February 27, 2019
Don't Throw Away RECIST 1.1 Quite Yet
Richard H Patt, Kohkan Shamsi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Onsite image evaluations and independent image blinded reads: close cousins or distant relatives?
Kohkan Shamsi, Richard H Patt
Investigative Radiology
|
October 13, 2006
A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data
Kohkan Shamsi, E Kent Yucel, Paul Chamberlin
European Radiology
|
June 28, 2006
Vasovist-enhanced MR angiography
Mathias Goyen, Kohkan Shamsi, Stefan O Schoenberg
Journal of Magnetic Resonance Imaging : JMRI
|
March 22, 2005
Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Jeffrey M Brody, Leah Schafer, Glenn A Tung, et al.
Radiology
|
September 11, 2004
MR coronary angiography with SH L 643 A: initial experience in patients with coronary artery disease
Christoph U Herborn, Michaela Schmidt, Oliver Bruder, et al.
Pancreas
|
April 6, 2026
pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer
Robert C G Martin, Eric Scheon, Narayanan Govindarajan, et al.
Radiology
|
August 29, 2003
Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers
Christoph U Herborn, Jörg Barkhausen, Ingo Paetsch, et al.
AJR. American Journal of Roentgenology
|
December 21, 2007
Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study
Enrique Bosch, Karl-Friedrich Kreitner, Mario Fava Peirano, et al.
Radiology
|
November 1, 2003
MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial
Pierre Perreault, Mark A Edelman, Richard A Baum, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Radiology
|
February 27, 2019
Don't Throw Away RECIST 1.1 Quite Yet
Richard H Patt, Kohkan Shamsi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Onsite image evaluations and independent image blinded reads: close cousins or distant relatives?
Kohkan Shamsi, Richard H Patt
Investigative Radiology
|
October 13, 2006
A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data
Kohkan Shamsi, E Kent Yucel, Paul Chamberlin
European Radiology
|
June 28, 2006
Vasovist-enhanced MR angiography
Mathias Goyen, Kohkan Shamsi, Stefan O Schoenberg
Journal of Magnetic Resonance Imaging : JMRI
|
March 22, 2005
Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Jeffrey M Brody, Leah Schafer, Glenn A Tung, et al.
Radiology
|
September 11, 2004
MR coronary angiography with SH L 643 A: initial experience in patients with coronary artery disease
Christoph U Herborn, Michaela Schmidt, Oliver Bruder, et al.
Pancreas
|
April 6, 2026
pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer
Robert C G Martin, Eric Scheon, Narayanan Govindarajan, et al.
Radiology
|
August 29, 2003
Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers
Christoph U Herborn, Jörg Barkhausen, Ingo Paetsch, et al.
AJR. American Journal of Roentgenology
|
December 21, 2007
Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study
Enrique Bosch, Karl-Friedrich Kreitner, Mario Fava Peirano, et al.
Radiology
|
November 1, 2003
MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial
Pierre Perreault, Mark A Edelman, Richard A Baum, et al.
Page
of 2